Phase II study of Vigil® DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Tuesday, November 29, 2016

Phase II study of Vigil® DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer



Phase II study of Vigil® DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer

Conclusion

In conjunction with the demonstrated safety, the high rate of induction of T-cell activation and correlation with improvement in RFS justify further Phase II/III assessment of Vigil.

0 comments :

Post a Comment

Your comments?